Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Am J Ther ; 24(4): e481-e484, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28692440

RESUMO

We describe a recent case of Stevens-Johnson Syndrome. A 49-year-old man was admitted to the Intensive Care Unit of an Anaesthesia and Resuscitation Department because of a Fournier gangrene that derived in a sepsis, ventilator-associated pneumonia, and renal failure. He was under treatment with cefepime and suffered a generalized status epilepticus, so started treatment with phenytoin. The next day he developed a "maculous cutaneous eruption in trunk and lower limbs" compatible with a Stevens-Johnson Syndrome. Stevens-Johnson Syndrome is a very severe and potentially fatal multiorganic disease, especially when present in critically ill patients, with a strong drug-related etiology, especially with antiepileptic drugs.


Assuntos
Antibacterianos/efeitos adversos , Anticonvulsivantes/efeitos adversos , Cefalosporinas/efeitos adversos , Fenitoína/efeitos adversos , Síndrome de Stevens-Johnson/terapia , Anticonvulsivantes/uso terapêutico , Cefepima , Estado Terminal , Gangrena de Fournier/complicações , Gangrena de Fournier/tratamento farmacológico , Humanos , Falência Renal Crônica/complicações , Masculino , Pessoa de Meia-Idade , Fenitoína/uso terapêutico , Pneumonia Associada à Ventilação Mecânica/complicações , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Sepse/complicações , Sepse/tratamento farmacológico , Estado Epiléptico/induzido quimicamente , Estado Epiléptico/tratamento farmacológico , Síndrome de Stevens-Johnson/etiologia
2.
Ann Pharmacother ; 48(7): 932-935, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24736949

RESUMO

OBJECTIVE: To describe a recent case of suspected interaction between oral cyclosporine modified and iron. CASE SUMMARY: A 33-year-old man underwent urgent cardiac transplantation for refractory cardiogenic shock caused by acute myocarditis. The patient had persistently low levels of cyclosporine despite a dose increase of the drug after the change of administration route from intravenous to oral. Spacing the administration of cyclosporine modified from oral iron resolved the problem. This drug interaction was reported as "probable" as determined by a Drug Interaction Probability Scale score of 7. Using this scoring system, the patient experienced a probable drug interaction between cyclosporine and iron both administered orally, and we surmise that the mechanism is that iron physicochemically destabilizes the cyclosporine microemulsion when both are administered concurrently. DISCUSSION: This may be because of the interaction between cyclosporine microemulsion and iron because this cation can destabilize the immunosuppressant dosage form. CONCLUSIONS: Taking into account that joint administration of oral iron and cyclosporine modified can generate a physicochemical interaction that involves a decrease in the absorption of cyclosporine modified, we believe that it is necessary to recommend spacing administrations of both drugs as well as monitoring levels of cyclosporine in order to ensure optimal levels of immunosuppression.

3.
Recurso na Internet em Espanhol | LIS - Localizador de Informação em Saúde, LIS-ES-PROF | ID: lis-42338

RESUMO

Manual en el que a través de casos clínicos se aborda la farmacoterapia de enfermedades con baja prevalencia, que disponen de tratamientos huérfanos y que afectan a pacientes de Castilla-La Mancha. Incluye diversas patologías como la enfermedad de Behcet, de Fabry, de Menkes, de Pompe, de Wilson, hemoglobinuria paroxística nocturna, mielofibrosis idiopática, tirosinemia, trombocitopenia inmune primaria y defectos del Ciclo de la Urea.


Assuntos
Serviço de Farmácia Hospitalar , Doenças Raras/tratamento farmacológico , Síndrome de Behçet/tratamento farmacológico , Doença de Fabry/tratamento farmacológico , Síndrome dos Cabelos Torcidos/tratamento farmacológico , Doença de Depósito de Glicogênio Tipo II/tratamento farmacológico , Hemoglobinúria Paroxística/tratamento farmacológico , Mielofibrose Primária/tratamento farmacológico , Tirosinemias/tratamento farmacológico , Trombocitopenia/tratamento farmacológico , Degeneração Hepatolenticular/tratamento farmacológico , Distúrbios Congênitos do Ciclo da Ureia/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...